

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Recombinant Human VEGF-D (C-6His) EBT-EPT213

Article Name	Recombinant Human VEGF-D (C-6His)
Biozol Catalog Number	EBT-EPT213
Supplier Catalog Number	EPT213
Alternative Catalog Number	EBT-EPT213-10
Manufacturer	ELK Biotechnology
Category	Proteine/Peptide
Product Description	Recombinant Human Vascular Endothelial Growth Factor D is produced by our Mammalian expression system and the target gene encoding Phe93-Ser201 is expressed with a 6His tag at the C-terminus....
Molecular Weight	Molecular weight: 13 KDa. Apparent molecular weight: 18 KDa, reducing conditions
UniProt	O43915
Purity	Greater than 95% as determined by reducing SDS-PAGE.

Application Notes

Redissolve: Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 μ g/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.. Endotoxin: Less than 0.1 ng/ μ g (1 EU/ μ g) as determined by LAL test. Biological activity: Immobilized Human VEGFR2-Fc(CatCJ92) at 5 μ g/ml (100 μ l/well) can bind Human VEGF-D-His(CatC498). The ED₅₀ of Human VEGF-D-His(CatC498) is 0.214 ug/ml. Background: Vascular endothelial growth factor D (VEGF-D) is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. It is highly expressed in lung, heart, small intestine and fetal lung, and at lower levels in skeletal muscle, colon, and pancreas. VEGF-D is growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. It may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. It undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3 receptors.